Newsroom

CSRxP Statement on New Data Showing Best-Selling Drug Prices Rising at Twice the Rate of Inflation

“When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.”

Read more

CSRxP Statement on AstraZeneca seeking “Orphan Drug” designation for widely-used cholesterol drug Crestor

“Abusing rules and regulations to keep competitors out of the market is common in the prescription drug industry, but AstraZeneca’s latest undertaking is especially egregious.”

Read more

CSRxP Statement on Medicare Trustees Report

“Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election.”

Read more

CSRxP Announces Support for Bipartisan CREATES Act

The Campaign for Sustainable Rx Pricing (CSRxP) announced its endorsement of the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act, a bill introduced today in the Unites States Senate.

Read more